Neurogene Inc. (NGNE) Stock

Neurogene Inc. (NGNE) is a Healthcare stock trading at $38.62 (as of 2026-08-21), with a market capitalization of $772.74M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neurogene Inc. develops genetic medicines focused on neurological diseases. Its pipeline includes an investigational AAV9 gene therapy for Rett syndrome (NGN-401) and a program for neuronal ceroid lipofuscinosis, subtype 5 (NGN-101).

Understand Neurogene Inc.: how it makes money

Neurogene Inc. develops investigational genetic medicines for neurological diseases, including NGN-401 (an AAV9 gene therapy for Rett syndrome) and NGN-101 for neuronal ceroid lipofuscinosis subtype 5, and it advances these product candidates through clinical trials.

The profit model is directly tied to the company’s ability to advance its investigational gene therapies in clinical development, since the current disclosed value is primarily in trial execution and resulting clinical data for NGN-401 and NGN-101.

Business quality (Weak): Clearly defined therapeutic programs (NGN-401 for Rett syndrome, NGN-101 for Batten disease) with concrete trial-operational KPIs, but it is still early-stage and does not show any disclosed segment revenue breakdown.

Bull case

  • Trial momentum for NGN-401’s registrational path: The company reports dosing progress in the Embolden Registrational Trial (Participants Dosed in the Embolden Registrational Trial).
  • Multi-site execution: It also discloses the Number of Embolden Trial Sites Initiated, which is a key operational lever for maintaining enrollment and execution pace.

Bear case

  • Execution and data risk remain central: Because NGN-401 and NGN-101 are investigational and tied to clinical trial results, the company’s trajectory depends on achieving enrollment, follow-up, and endpoints as the studies progress.
  • Current operations show large losses: For the period ended 2026-03-31, the company reported revenue of 0.0B and an operating margin of -1475.0%, indicating material losses.
Valuation — source: SEC EDGAR (first-party)
Price$38.62
Market Cap$772.74M
Price / Book3.56
Price / Sales117.65
FCF Yield-21.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-0.9%
FCF Growth (YoY)9.7%
Financial Health — source: SEC EDGAR
Altman Z-Score13.38 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSAMSARA BIOCAPITAL, LLC ($34.62M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORachel L. McMinn
Employees107
CountryUS
IPO Date2014-03-07

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Gyre Therapeutics, Inc. (GYRE)
  • Nuvectis Pharma, Inc. (NVCT)
  • Esperion Therapeutics, Inc. (ESPR)
  • Monopar Therapeutics Inc. (MNPR)
  • CytomX Therapeutics, Inc. (CTMX)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Zevra Therapeutics, Inc. (ZVRA)
  • Assembly Biosciences, Inc. (ASMB)
NGNE earnings history · NGNE institutional & insider holders · NGNE KPIs & operating metrics · NGNE financials · NGNE investor presentations & press releases · NGNE SEC filings · NGNE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.